How Should Medical Device Labeling and Instructions for Use Be Localized for EU MDR Registration?

Answer: Localizing medical device labeling and instructions for use (IFU) for EU MDR registration should begin with product classification and a documentation gap assessment, followed by confirmation of whether existing NMPA, CE, FDA, ISO 13485, or other market materials can be reused; the localization itself must align with MDR technical documentation, authorized representative, importer, language, QMS evidence, and change-control requirements.

Published: 2026-07-15 20:46 | Updated: 2026-07-15 20:46

Key Summary

EU MDR technical documentation for medical devices must cover product description, design and manufacturing information, GSPR compliance, risk management, performance verification, clinical evaluation, labeling and IFU, PMS/PMCF, and the declaration of conformity. Companies cannot simply reuse old MDD files; they must reorganize the technical documentation according to the MDR evidence chain.

For Chinese medical device manufacturers, a prudent approach is to first complete product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused.

Target market registration typically affects the technical file, authorized representative, importer cooperation, label language, QMS evidence, and subsequent change maintenance. If a company proceeds only by asking which documents to submit, it is likely to encounter deficiencies or rework in model coverage, evidence chain consistency, label claims, and certificate control.

AIMEILI recommends that companies include this issue in a unified GHWP member state and multi-country access strategy, using a reusable core technical file to support localization in different markets, rather than redoing materials on an ad hoc basis for each country.

Companies should also make project-based judgments in light of the latest requirements of the target country regulatory authority, existing technical file basis, product risk class, and launch plan, avoiding mechanical preparation based only on a document checklist.

This article is compiled from AIMEILI registration practical question bank, medical device international registration knowledge base, and public regulatory information; specific projects should be subject to the latest requirements of the target country regulatory authority and the product data basis.

Applicable Scenarios and Core Questions

Companies searching for how to localize medical device labeling and IFU for EU registration are usually not looking for a conceptual explanation. They want to know whether existing materials can support target market submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues affect launch plans. Behind this question are often product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for one country alone is not enough. A more valuable approach is to first develop reusable versions of core technical files, QMS evidence, performance verification, clinical evidence, and labeling/IFU, and then adapt them locally according to each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm the intended use, mechanism of action, use scenario, body contact method, duration of use, whether the product is sterile, whether it is active, and whether it contains software or IVD attributes, and then determine the risk class and submission pathway. If the pathway is wrong, subsequent translation, notarization, authorization, testing, and supplementary materials will all deviate from the correct direction.

For target market projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal materials. If these issues are left vague in commercial contracts, market control can easily be affected later.

Materials and Evidence

Common materials include product description, model specification matrix, intended use, risk classification basis, ISO 13485 or applicable QMS certificate, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling and IFU, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance materials.

The key to material quality is not quantity but consistency. IFU claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support one another. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA materials without reorganizing the evidence according to the target market pathway.
• Having too many model specifications while test reports, clinical evidence, or label coverage are insufficient.
• Selecting a local agent only based on sales cooperation, without clarifying regulatory responsibility, certificate control, and post-market maintenance duties.
• Inconsistent claims among labels, IFU, promotional materials, and registration materials, leading to deficiencies or post-market compliance risks.
• Failure to plan multi-country material reuse in advance, resulting in repeated preparation for each country and amplified cost and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation basis, avoiding the discovery of key evidence gaps only after submission.

• Organize the target product list, model specification matrix, and intended use statement.
• Verify whether existing NMPA, CE, FDA, or other market registration materials can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English IFU.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target country gap assessment table, specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies not understand target market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, and then converting it according to national requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than ad hoc supplementation country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear numerous, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic materials be used directly for target market registration?

Domestic materials can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the material structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

Local agents typically participate in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger that manages the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify documentation gaps in a timely manner and allows management to judge whether the project will affect the launch plan.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established, clarifying which materials can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labeling and IFU, clinical evaluation, risk management, performance verification, and QMS certificates must remain version-consistent.

• Confirm target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

QMS and Evidence Consistency

From a registration review perspective, QMS materials are not an isolated certificate. Regulatory authorities usually check whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical file are consistent. If the ISO 13485 certificate coverage does not match the submitted product, or if the manufacturing address, model specifications, IFU version, and test reports are inconsistent, even if the company has prepared many documents, supplementary explanations may still be required.

Companies should establish an evidence consistency checklist before submission, matching product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling/IFU version, and QMS certificate item by item. Although this action seems basic, it can significantly reduce the probability of deficiencies, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product lines.

Localization Conversion and Agent Responsibilities

Target market registration projects typically involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market materials, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance. Once a manufacturing address change, model expansion, IFU update, or agent replacement occurs, it is easy for the certificate and market sales to become disconnected.

AIMEILI recommends that companies include this issue in annual international registration planning: first clarify target market priorities, then establish a reusable document package and national gap list, and finally arrange submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency in a single country, but more importantly to enable companies to form a replicable overseas compliance capability and reduce the cost of starting from scratch each time they enter a new market.

Continue Reading

Previous: How to organize EU MDR technical documentation for medical devices?

Next: How to prepare clinical evaluation materials for EU MDR medical device registration?

Recommended reading:

• How to choose a local agent for medical device registration in Brazil?
• How are authorized representative responsibilities divided for medical device registration in Brazil?
• Why does the registration cycle for medical device registration in Brazil get extended?
• What are common reasons for deficiency responses in medical device registration in Brazil?
• How to conduct post-market surveillance for medical device registration in Brazil?
• When must changes be reported for medical device registration in Brazil?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary reference.

Applicability boundary: This article is intended for preliminary understanding, material preparation, and project planning, and does not replace the formal requirements of the target country regulatory authority, testing conclusions, or legal opinions.